Gilead's Lucrative Hep C Patents Face PTAB Assault

By Jeff Overley (October 26, 2017, 5:48 PM EDT) -- A nonprofit group focused on drug competition is attacking six key patents for Gilead Sciences Inc.'s blockbuster portfolio of hepatitis C drugs, telling the Patent Trial and Appeal Board that a crucial active ingredient was created using obvious scientific approaches.

The Initiative for Medicines, Access & Knowledge Inc. said Wednesday that it filed petitions for inter partes review at the PTAB in hopes of clearing the way sooner for generic versions of Gilead's three hep C drugs: Sovaldi, Harvoni and Epclusa.

All three drugs boast remarkable cure rates for hepatitis C, a viral infection that can cause severe liver damage. But...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!


Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!